Secukinumab Sets New Benchmark in Psoriasis Treatment with 5-Year Phase 3 Data
The drug is the first and only fully-human antagonist showing sustained skin clearance rates at 5 years.
Read More
Summit Therapeutics Wins $62M to Spur Development of Ridinilazole for C. Difficile
The BARDA contract funds a specified portion of estimated costs related to the drug’s development.
Upadacitinib Meets Endpoints in Second Phase 3 Study for Rheumatoid Arthritis
The study showed positive results in a difficult-to-treat patient population.
Lilly's Lasmiditan Drastically Reduces Pain in Migraine Patients
Majority of patients experienced relief from migraine pain, consistent with findings from first pivotal Phase III study.
Galcanezumab Shows Positive Long-Term Safety Results for Migraine Patients
Over a 12-month period, the drug showed a statistically significant reduction in the number of monthly migraine headache days.
Upadacitinib Meets Endpoints in Phase 2b Study for Atopic Dermatitis
The study showed positive results for the drug and no new safety signals.
Secnidazole Meets Primary Endpoints in Phase 3 Trials for Bacterial Vaginosis
If approved, the drug will be the first and only single-dose oral therapy available or the condition.